Piper Sandler lowered the firm’s price target on PacBio (PACB) to $1.25 from $2 following quarterly results. The firm keeps a Neutral rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PACB:
- PacBio board: Independent investigation concludes allegations unsubstantiated
- Pacific Biosciences: Strategic Shift to Long-Read Sequencing Fuels Buy Rating Amid Strong Q1 Performance
- Pacific Biosciences’ Earnings Call: Achievements and Challenges
- Pacific Biosciences’ Strategic Focus on Long-Read Sequencing and International Expansion Drives Growth Potential
- PacBio Reports Q1 2025 Financial Results Amid Restructuring
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue